Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers Health (NYSE: HIMS) appointed neuroscientist and Stanford professor Andrew Huberman to its board of directors. Huberman is a tenured professor in Stanford University School of Medicine’s Departments of Neurobiology and Ophthalmology and has authored or co-authored more than 75 peer-reviewed articles.
He will also serve as a scientific and brand marketing advisor to Hims & Hers and separately provide additional marketing support through his Huberman Lab podcast.
Hims & Hers Health (NYSE: HIMS) reported third-quarter 2026 revenue of approximately $890 million, up 49% year over year. Subscribers rose 13% to 2.788 million, while monthly revenue per average subscriber increased 30% to $105. U.S. revenue grew 21%; revenue outside the U.S. rose 321%.
Gross margin fell to 57% from 74%. The company posted a $33.040 million net loss versus $15.774 million net income, while adjusted EBITDA increased to $82.4 million from $78.4 million. Operating cash flow fell to $65.4 million from $148.7 million, and free cash flow declined to $26.0 million from $79.4 million.
The company tightened its full-year revenue outlook to $3.13 billion–$3.15 billion and reduced adjusted EBITDA guidance to $257 million–$277 million. For the fourth quarter, it expects revenue of $875 million–$895 million and adjusted EBITDA of $70 million–$90 million.
Eli Lilly (LLY) and Hims & Hers Health (HIMS) announced an agreement to offer Lilly’s obesity medicines through the Hims & Hers platform. Eligible patients prescribed Zepbound (tirzepatide) or Foundayo (orforglipron) can access the same self-pay prices available to any patient without leaving the platform. Prices start at $149 per month for Foundayo and $299 per month for Zepbound, with medicines shipped directly to patients’ homes.
Hims & Hers has committed not to offer compounded copies of Lilly’s GLP-1 medicines. Both companies also committed to protecting independent clinical decisions, with providers determining the appropriate treatment for each patient.
Hims & Hers Health (NYSE: HIMS) added Grüns, Medjet, Tonal and Viome to its subscriber benefits program, expanding its partner offerings. The program now includes 14 partners, up from two at its March launch.
The new offers include $30 off a first Grüns order, approximately 30% off Medjet’s standard retail rates and $1,000 off Tonal 2 hardware. Viome offers $100 off its Full Body Intelligence test and one free month of Precision Supplements with the purchase of two months. The additions cover nutrition, air medical transport, at-home strength training and personalized nutrition insights.
Benefits are immediately available only to active subscribers. Some offers include free trials or introductory pricing; partner terms apply, and prescription products are not included.
Hims & Hers Health (HIMS) launched injectable and oral testosterone replacement therapies for eligible men, expanding its testosterone care offering. The additions include a twice-weekly compounded injection under the skin, weekly intramuscular generic testosterone cypionate, and FDA-approved oral Kyzatrex. They build on the existing Testosterone Rx+ offering, which includes enclomiphene to stimulate the body’s own testosterone production.
The company said testosterone was scaling faster than any specialty outside weight loss as of Q2 2026, three quarters after launch. Treatment requires laboratory testing, a prescription and a provider’s assessment of medical suitability. The program includes follow-up testing and ongoing clinical support. Availability does not extend to all 50 states; compounded drugs are not FDA-approved or evaluated by the agency for safety, effectiveness or quality.
Hims & Hers (NYSE: HIMS) will report third quarter 2026 financial results after the market closes on November 9, 2026. The company will host a live conference call at 5:00 p.m. ET that day to discuss the results. A live audio webcast will be available at investors.hims.com and archived for one year.
Hims & Hers (HIMS) launched Hers in Australia, rebranding Juniper and completing the rollout of its platform in the country. Juniper, Eucalyptus' women's health platform, has served Australian patients since 2021. The rebrand follows Pilot's transition to Hims in August and the company's acquisition of Eucalyptus earlier this year.
Hers offers care spanning hair regrowth, menopause and perimenopause, and weight management. Services include access to medication, nutrition and fitness support, and a care team available 24/7. Weight-management patients also receive a digital companion grounded in more than 20 peer-reviewed studies focused on women's needs. Women may request a female practitioner across specialties. Gus Wood oversees Australia as general manager, while Dr. Matt Vickers serves as chief medical officer of Hims & Hers Australia.
Hims & Hers Health (HIMS) has appointed Jon Franklin as Chief Accounting Officer to oversee the company’s accounting organization. He reports to Chief Financial Officer Yemi Okupe and succeeds Irene Becklund, who announced her departure in July after seven years at the company. Becklund will serve as an advisor to support the transition.
Franklin is a Certified Public Accountant with two decades of technical accounting experience. He joins from Rivian, where he served as Vice President, Corporate Controller, responsible for technical accounting, corporate accounting and financial reporting. Previously, he spent more than 15 years in PwC’s Assurance division.
Hims & Hers Health (NYSE: HIMS) named Kultar Garcha and Matt Vickers to regional chief medical officer roles as it expands internationally. Garcha will serve as Chief Medical Officer of the UK and EMEA, covering Europe, the Middle East and Africa. Vickers will serve as Chief Medical Officer of Hims Australia. Both join the global medical leadership team led by Pat Carroll.
Garcha will oversee clinical quality, patient safety and prescribing standards across the UK and EMEA. He has over two decades of experience across public and private health systems, including almost 15 years as a practicing NHS general practitioner. Vickers will lead clinical strategy in Australia. He is a practicing general practitioner with more than a decade of family medical practice experience and has led health-tech efforts at Eucalyptus since 2019.
Hims (NYSE:HIMS) is launching the Hims brand in Australia, following its earlier acquisition of Eucalyptus, by rebranding Eucalyptus' men's health platform Pilot. Effective immediately, Pilot becomes Hims, with patients retaining existing treatment plans and provider relationships while gaining access to Hims' personalised digital care platform.
According to Hims & Hers, Australian men will receive 24/7 access to a Care Team, expanded services for sexual health, weight loss, and hair loss, and new combined treatment options, including for premature ejaculation and cholesterol management. Local leadership is led by Tim Doyle and Gus Wood, with Dr. Matt Vickers serving as Chief Medical Officer for Hims Australia.